Streetbeat News

Revenues

NCNO

Ncino (NASDAQ:NCNO) has received mixed analyst ratings over the last three months, with a shift towards a more bullish outlook in the last 30 days. The average 12-month price target for NCNO is $36.33, reflecting an 8.77% increase from the previous target of $33.40. Analysts from firms including Keefe, Bruyette & Woods, Morgan Stanley, Baird, Needham, and Piper Sandler have updated their ratings and price targets, indicating a dynamic market response to Ncino's performance. Ncino, a provider of cloud-based software for financial institutions, has shown impressive revenue growth of 13.29% as of January 31, 2024, but its revenue growth lags behind industry peers. Despite this, Ncino has a strong net margin of 0.94% and an exceptional return on assets (ROA) of 0.09%, though its return on equity (ROE) is below industry averages.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 9:00 pm

JZ

Jianzhi Education Technology reported a 12.9% decrease in FY23 revenue, totaling RMB440.5 million or approximately $62 million.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:35 pm

RICK

RCI Hospitality reported a 4.2% year-over-year increase in Q2 sales for its nightclubs, while its Bombshells restaurant segment experienced a 10.4% decline in sales.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:14 pm

ICCC

ImmuCell, identified by the symbol ICCC, reported preliminary, unaudited sales results for Q1 2024, showing a significant increase of 111% year-over-year to $7.3M. Additionally, the company's total sales for the twelve-month period ending March 31, 2024, increased by 33% compared to the same period the previous year.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:09 pm

UAL

United Airlines Holdings (NASDAQ:UAL) has received mixed analyst ratings over the past three months, with a shift towards a more neutral stance in the last 30 days. The average 12-month price target for UAL has been adjusted to $54.25, down from $59.00, reflecting a decrease in analyst expectations. The company's financial performance shows strong market recognition, revenue growth, and profitability, with a notable ROE and ROA, indicating efficient use of assets and equity capital.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

LDOS

Recent analyst ratings for Leidos Holdings (NYSE:LDOS) show a predominantly bullish outlook, with 8 analysts updating their views. The average 12-month price target has been raised to $140.5, indicating a 12.51% increase from the previous target of $124.88. Analysts from firms like Truist Securities, Wells Fargo, and B of A Securities have raised their price targets, reflecting positive sentiment towards LDOS's market position and financial performance. The company has shown solid revenue growth, impressive net margin, and strong ROE and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

BYD

Recent analyst ratings for Boyd Gaming (NYSE:BYD) show a mix of perspectives, with the latest 12-month price target averaging $75.22, up 1.48% from the previous $74.12. Analyst actions include various adjustments to ratings and price targets, reflecting changing market dynamics and company performance. Boyd Gaming's financials indicate strong market recognition, revenue growth, and profitability, with a notable ROE and ROA surpassing industry standards.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

MURA

Mural Oncology presented preclinical data for its IL-18 and IL-12 programs at the 2024 American Association For Cancer Research Annual Meeting, indicating progress in their development. The company expects to nominate candidates for each program later this year. The data showed that their IL-18 variant, with enhanced half-life and resistance, demonstrated durable immunological effects. Additionally, their engineered IL-12 approach aims to reduce toxicity while maintaining efficacy.

Portfolio Pulse from Benzinga Newsdesk

April 09, 2024 | 8:01 pm

AMP

Analyst ratings for Ameriprise Financial (NYSE:AMP) have varied over the last quarter, with recent updates showing a mix of bullish, somewhat bullish, and indifferent stances. The average 12-month price target has risen to $431.5, indicating a 5.86% increase from the previous target. Ameriprise Financial, a major player in asset and wealth management with $1.4 trillion in assets under management, has shown a revenue growth of 8.98% and an ROE of 8.81%, despite a net margin below industry averages and an ROA of 0.22%.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:01 pm

AUGX

Analyst ratings for Augmedix (NASDAQ:AUGX) show a mix of opinions, with recent actions including both upgrades and downgrades. The average 12-month price target is $5.00, with a high of $5.50 and a low of $4.50, marking a 14.24% decline from the previous average. Augmedix's financial performance shows strong revenue growth and net margin, but challenges in asset utilization and higher debt levels. Analysts' ratings and price targets reflect their views on the company's future performance relative to market conditions.

Portfolio Pulse from Benzinga Insights

April 09, 2024 | 8:00 pm